FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947966909> ?p ?o ?g. }

• W2947966909 endingPage "262" @default.
• W2947966909 startingPage "262" @default.
• W2947966909 abstract "Nintedanib is a tyrosine kinase inhibitor that has been shown to suppress progression of idiopathic pulmonary fibrosis (IPF). The efficacy and tolerability of nintedanib for IPF has been previously proven in the INPULSIS® and INPULSIS-On® trials. The aim of our study was to clarify the tolerability of nintedanib in the real world for severe IPF patients who were unable to enter the INPULSIS® and INPULSIS-On® trials.We retrospectively investigated medical records of 8 patients with severe IPF and 14 patients with non-severe IPF who had been treated with nintedanib. The criteria to define severe IPF were forced vital capacity (FVC) of <50% predicted and/or diffusing capacity of the lung for carbon monoxide/alveolar volume (DLCO/VA) of <30% predicted or unmeasurable. Severity of adverse event was evaluated using the Common terminology criteria for each adverse event version 4.0. We compared changes in FVC and serum KL-6 level, incidence and severity of adverse events, and incidence of permanent or temporary discontinuation of nintedanib in between severe and non-severe IPF groups.The median treatment period was 578.5 days. The most frequent adverse event was diarrhea (73%). Only 2 patients required permanent discontinuation of nintedanib due to adverse events. There was no difference in incidence or severity of adverse events or incidence of permanent or temporary discontinuation of nintedanib in between severe and non-severe IPF groups. Among subjects, decline in FVC during 6 months post-nintedanib treatment were significantly lower than prior to treatment, but change in serum KL-6 level showed no significant difference between these 2 timepoints.Our study showed that nintedanib was tolerable for IPF patients who would not have been eligible for entry into previous clinical trials due to low pulmonary function. Although therapeutic strategy for severe IPF should be planned carefully, initiation of nintedanib treatment should not be dismissed solely for reasons of low pulmonary function." @default.
• W2947966909 created "2019-06-07" @default.
• W2947966909 creator A5005376778 @default.
• W2947966909 creator A5018352368 @default.
• W2947966909 creator A5019857625 @default.
• W2947966909 creator A5033081610 @default.
• W2947966909 creator A5045491062 @default.
• W2947966909 creator A5065970034 @default.
• W2947966909 creator A5072804940 @default.
• W2947966909 creator A5076885089 @default.
• W2947966909 creator A5079620485 @default.
• W2947966909 creator A5086830418 @default.
• W2947966909 creator A5088225787 @default.
• W2947966909 date "2019-06-01" @default.
• W2947966909 modified "2023-10-16" @default.
• W2947966909 title "A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world" @default.
• W2947966909 cites W1913616561 @default.
• W2947966909 cites W1938547050 @default.
• W2947966909 cites W1954728404 @default.
• W2947966909 cites W1964124382 @default.
• W2947966909 cites W2058408736 @default.
• W2947966909 cites W2063946490 @default.
• W2947966909 cites W2106320546 @default.
• W2947966909 cites W2108581097 @default.
• W2947966909 cites W2118749321 @default.
• W2947966909 cites W2121910720 @default.
• W2947966909 cites W2125553008 @default.
• W2947966909 cites W2138871107 @default.
• W2947966909 cites W2143551777 @default.
• W2947966909 cites W2143997148 @default.
• W2947966909 cites W2146783450 @default.
• W2947966909 cites W2149661971 @default.
• W2947966909 cites W2161625871 @default.
• W2947966909 cites W2462000645 @default.
• W2947966909 cites W2753475654 @default.
• W2947966909 cites W2788452276 @default.
• W2947966909 cites W2889197569 @default.
• W2947966909 cites W2890575335 @default.
• W2947966909 doi "https://doi.org/10.21037/atm.2019.05.33" @default.
• W2947966909 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6614312" @default.
• W2947966909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31355229" @default.
• W2947966909 hasPublicationYear "2019" @default.
• W2947966909 type Work @default.
• W2947966909 sameAs 2947966909 @default.
• W2947966909 citedByCount "18" @default.
• W2947966909 countsByYear W29479669092019 @default.
• W2947966909 countsByYear W29479669092020 @default.
• W2947966909 countsByYear W29479669092021 @default.
• W2947966909 countsByYear W29479669092022 @default.
• W2947966909 countsByYear W29479669092023 @default.
• W2947966909 crossrefType "journal-article" @default.
• W2947966909 hasAuthorship W2947966909A5005376778 @default.
• W2947966909 hasAuthorship W2947966909A5018352368 @default.
• W2947966909 hasAuthorship W2947966909A5019857625 @default.
• W2947966909 hasAuthorship W2947966909A5033081610 @default.
• W2947966909 hasAuthorship W2947966909A5045491062 @default.
• W2947966909 hasAuthorship W2947966909A5065970034 @default.
• W2947966909 hasAuthorship W2947966909A5072804940 @default.
• W2947966909 hasAuthorship W2947966909A5076885089 @default.
• W2947966909 hasAuthorship W2947966909A5079620485 @default.
• W2947966909 hasAuthorship W2947966909A5086830418 @default.
• W2947966909 hasAuthorship W2947966909A5088225787 @default.
• W2947966909 hasBestOaLocation W29479669091 @default.
• W2947966909 hasConcept C126322002 @default.
• W2947966909 hasConcept C165637977 @default.
• W2947966909 hasConcept C197934379 @default.
• W2947966909 hasConcept C2777714996 @default.
• W2947966909 hasConcept C2778341716 @default.
• W2947966909 hasConcept C2778375690 @default.
• W2947966909 hasConcept C2778715236 @default.
• W2947966909 hasConcept C2780171596 @default.
• W2947966909 hasConcept C3018587741 @default.
• W2947966909 hasConcept C55520419 @default.
• W2947966909 hasConcept C71924100 @default.
• W2947966909 hasConceptScore W2947966909C126322002 @default.
• W2947966909 hasConceptScore W2947966909C165637977 @default.
• W2947966909 hasConceptScore W2947966909C197934379 @default.
• W2947966909 hasConceptScore W2947966909C2777714996 @default.
• W2947966909 hasConceptScore W2947966909C2778341716 @default.
• W2947966909 hasConceptScore W2947966909C2778375690 @default.
• W2947966909 hasConceptScore W2947966909C2778715236 @default.
• W2947966909 hasConceptScore W2947966909C2780171596 @default.
• W2947966909 hasConceptScore W2947966909C3018587741 @default.
• W2947966909 hasConceptScore W2947966909C55520419 @default.
• W2947966909 hasConceptScore W2947966909C71924100 @default.
• W2947966909 hasIssue "12" @default.
• W2947966909 hasLocation W29479669091 @default.
• W2947966909 hasLocation W29479669092 @default.
• W2947966909 hasLocation W29479669093 @default.
• W2947966909 hasLocation W29479669094 @default.
• W2947966909 hasOpenAccess W2947966909 @default.
• W2947966909 hasPrimaryLocation W29479669091 @default.
• W2947966909 hasRelatedWork W2106320546 @default.
• W2947966909 hasRelatedWork W2394430582 @default.
• W2947966909 hasRelatedWork W3047341706 @default.
• W2947966909 hasRelatedWork W3136371725 @default.
• W2947966909 hasRelatedWork W3163230142 @default.
• W2947966909 hasRelatedWork W3215070884 @default.

• next